Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr

Lupin is the 6th largest company in the Indian Pharmaceutical Market

Sandu Pharmaceuticals launches Sandu Kumarvin

Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.

Merck KGaA posts higher earnings, profits across business segments

Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million

Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery

The WAVEsystem with the WAVEcontrol 4.0 embedded

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

PIB: Quality control of Ayush drugs

PIB: Development of Ayush entrepreneurship

Ministry of Ayush signed a MoU with Ministry of Micro, Small & Medium Enterprises (MSME) for the promotion of Ayush enterprises.

Ensure time-bound Infrastructure development of Ayush National Institutes/Central Councils projects: Sonowal

Ministry of Ayush has fast tracked up-gradation and construction of various Ayush Infrastructure across the country

PIB: Pharmaceutical industry in Maharashtra

The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.